Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
表达KIR2DL2和KIR3DL1及其配体(HLA-C1和HLA-Bw4)的滤泡性淋巴瘤患者接受利妥昔单抗治疗后,预后有所改善。
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1186/s40425-019-0538-8
Erbe, Amy K; Wang, Wei; Carmichael, Lakeesha; Hoefges, Anna; Grzywacz, Bartosz; Reville, Patrick K; Ranheim, Erik A; Hank, Jacquelyn A; Kim, KyungMann; Seo, Songwon; Mendonca, Eneida A; Song, Yiqiang; Kenkre, Vaishalee P; Hong, Fangxin; Gascoyne, Randy D; Paietta, Elisabeth; Horning, Sandra J; Miller, Jeffrey S; Kahl, Brad; Sondel, Paul M